Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: A novel randomized incremental recruitment study

JAMA

Volumn 293, Issue 22, 2005, Pages 2719-2725

  Grant, Alison D ^a   Charalambous, Salome ^b   Fielding, Katherine L ^a   Day, John H ^a,b   Corbett, Elizabeth L ^a   Chaisson, Richard E ^c   De Cock, Kevin M ^a   Hayes, Richard J ^a   Churchyard, Gavin J ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AURUM INSTITUTE   (South Africa)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SELF ADMINISTRATION; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINER; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAMPLE SIZE; SILICOSIS; SKIN ALLERGY; SOUTH AFRICA; WORKPLACE; AIDS RELATED COMPLEX; MINING; RISK FACTOR; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; HUMANS; INCIDENCE; ISONIAZID; MALE; MINING; RISK FACTORS; SILICOSIS; SOUTH AFRICA; TUBERCULOSIS;

EID: 20144378528     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.22.2719     Document Type: Article

References (31)

1. Cantwell MF, Binkin NJ. Impact of HIV on tuberculosis in sub-Saharan Africa: a regional perspective. Int J Tuberc Lung Dis. 1997;1:205-214.
2. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS. 1997;11(suppl B):S115-S123.
3. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
4. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis. 1999;3:4-11.
5. De Cock KM, Chaisson RE. Will DOTS do it? a reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999;3:457-465.
6. Corbett EL, Churchyard GJ, Charalambous S, et al. Morbidity and mortality in South African gold miners: the impact of untreated HIV disease. Clin Infect Dis. 2002;34:1251-1258.
7. Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med. 1994;150:1460-1462.
8. Churchyard GJ, Kleinschmidt I, Corbett EL, Mulder D, De Cock KM. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis. 1999;3:791-798.
9. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a metaanalysis of randomized controlled trials. AIDS. 1999; 13:501-507.
10. World Health Organization Global Tuberculosis Programme. Policy Statement on Preventive Therapy Against Tuberculosis in People Living With HIV. Geneva, Switzerland: World Health Organization; 1998. WHO/TB/98.255.
11. Ayles H, Mukombo D, Godfrey-Faussett P. Is it feasible to administer TB preventive therapy in Lusaka? Presented at: XIII International Conference on AIDS; Durban, South Africa; July 9-14, 2000. Abstract ThPeB5212.
12. Aisu T, Raviglione MC, van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS. 1995;9:267-273.
13. Charalambous S, Grant AD, Day JH, et al. Feasibility and acceptability of a specialist clinical service for HIV-infected mineworkers in South Africa. AIDS Care. 2004;16:47-56.
14. The Gambia Hepatitis Study Group. The Gambia Hepatitis Intervention Study. Cancer Res. 1987;47:5782-5787.
15. Cowie RL. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Tuber Lung Dis. 1996;77:239-243.
16. World Health Organization. Acquired immunodeficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec. 1990;65:221-224.
17. Guidelines for the Use of ILO International Classification of Radiographs of Pneumoconiosis. Geneva, Switzerland: International Labour Office; 1981. Series 22: Occupational Safety and Health.
18. Clayton D. Random effects Poisson regression and recurrent events data. Available at: http://www.stata .com/meeting/4uk/random.html. Accessed April 13, 2005.
19. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ. 1998;317:625-629.
20. Quigley MA, Mwinga A, Hosp M, et al. Longterm effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15:215-222.
21. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:2137-2147.
22. Churchyard GJ, Charalambous S, Moloi V, et al. Provisional assessment of the impact of adding sputum screening to existing active case finding methods in a gold mining workforce. 2002. Safety in Mines Research Advisory Committee. Available at: http: //www.simrac.co.za. Accessed April 20, 2005.
23. Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170:673-679.
24. Antonucci G, Girardi E, Raviglione MC, Ippolito G; Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA. 1995;274:143-148.
25. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064.
26. Churchyard GJ, Fielding KL, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS. 2003;17:2063-2070.
27. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
28. Corbett EL, Currie C, Churchyard GJ, Williams BG. Strategies for reducing the burden of TB infection and disease in high HIV prevalence populations: modelling the impact of active case finding, antiretrovirals and preventive therapy. Presented at: XIII International Conference on AIDS; Barcelona, Spain; July 7-12, 2002. Abstract WeOrC1312.
29. Godfrey-Faussett P, Ayles H. Can we control tuberculosis in high HIV prevalence settings? Tuberculosis (Edinb). 2003;83:68-76.
30. Comstock GW. Isoniazid prophylaxis in an undeveloped area.AmRev Respir Dis. 1962;86:810-822.
31. Ferebee S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106.